Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 8/20 | 0.59 |
| ▸ | SCN1A | P35498 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864745 | 0.89 | MAPT (0.57) | SCN8ASCN1AMAPTPKMMAPK1 | |
| SCHEMBL5864619 | 0.83 | SCD (0.52) | SCN8AMAPTMAPK1SCDSMN1; SMN2 | |
| SCHEMBL5865015 | 0.83 | SCN8A (0.59) | SCN8ASCN1ASCN9ASIGMAR1ACHE | |
| SCHEMBL5864902 | 0.80 | SCN1A (0.55) | SCN8ASCN1AMAPTPKMMAPK1 | |
| SCHEMBL21306435 | 0.76 | MAPK1 (0.60) | MAPTPKMMAPK1RAB9ASIGMAR1 | |
| SCHEMBL5865147 | 0.76 | SCD (0.67) | MAPTMAPK1RAB9ASCDSMN1; SMN2 | |
| SCHEMBL5864941 | 0.76 | SCD (0.56) | MAPTMAPK1SCDSMN1; SMN2 | |
| SCHEMBL5865016 | 0.76 | SCN8A (0.49) | SCN8ASCN1AMAPTRAB9ASCD | |
| SCHEMBL27265100 | 0.75 | HSD17B10 (0.53) | MAPTPKMRAB9ASCDSMN1; SMN2 | |
| SCHEMBL11241454 | 0.75 | CYP19A1 (0.60) | MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | SCN8A 763/4885SCN1A 572/4885MAPT 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.